martes, 6 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 4, 2026

Avery Dennison outlines 6% Q1 2026 EPS growth target as high-value category mix accelerates

View original at seekingalpha.com
Avery Dennison outlines 6% Q1 2026 EPS growth target as high-value category mix accelerates Earnings Call Insights: Avery Dennison Corporation (AVY) Q4 2025 MANAGEMENT VIEW * Deon Stander, President, CEO & Director, stated the company delivered adjusted EPS of $9.53 and $707 million of adjusted free cash flow for 2025,…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Base volumes were a bit soft in the quarter, and productivity actions were used to offset wage inflation, with some onetime items and extra calendar days impacting results

    80% confidence
  • High-value categories in Solutions Group provided necessary offset to base solutions which continue to be impacted by tariff-related uncertainty

    80% confidence
  • The Walmart announcement increased pipeline interest in Intelligent Labels

    80% confidence
  • The Walmart announcement increased pipeline interest, indicating positive market reception

    80% confidence
  • Base volumes were a bit soft in the quarter, and productivity actions were used to offset wage inflation, with some onetime items and extra calendar days impacting results

    80% confidence
  • In Q4, the company delivered solid adjusted earnings per share of $2.45, up 3% compared to prior year

    80% confidence
  • Ongoing investments in digital capabilities, automation, and AI will enable additional operational productivity and fixed cost innovation, strengthen service and quality, shorten innovation cycles and provide more data-driven solutions

    80% confidence
  • High-value categories margins are a number of points above company average, and significantly above base categories

    80% confidence
  • High-value categories helped balance base categories, which were down low single digits in the quarter on softer customer volumes

    80% confidence
  • Company delivered adjusted EPS of $9.53 and $707 million of adjusted free cash flow for 2025, demonstrating the durability of the franchise and ability to activate multiple levers across a range of macro scenarios

    80% confidence
  • Given key economic indicators remain largely consistent with 2025 levels, not planning for any macroeconomic tailwinds in the near term

    80% confidence
  • High-value categories expected to grow at mid-single-digit plus

    80% confidence
  • Expect restructuring savings of approximately $50 million as the company continues to execute productivity playbook, and expect normalization of majority of 2025 temporary savings related to lower incentive compensation costs

    80% confidence
  • Apparel business saw a 7% decline, greater than anticipated, primarily due to changes in retailer ordering behavior amid tariff uncertainty

    80% confidence
  • Pricing typically follows raw material input cost changes, with productivity actions aimed at offsetting wage inflation

    80% confidence
  • Compliance enforcement in general retail is expected to provide a tailwind, and the company is expanding logistics pilots with new customers

    80% confidence
  • Base volumes were a bit soft in the quarter

    80% confidence
  • We continue to drive ongoing productivity all the time in terms of ELS savings, looking at reducing scrap, being more efficient in our operations

    80% confidence
  • The company delivered adjusted EPS of $9.53 and $707 million of adjusted free cash flow for 2025, demonstrating the durability of the franchise and ability to activate multiple levers across a range of macro scenarios

    80% confidence
  • In the fourth quarter, we delivered solid adjusted earnings per share of $2.45, up 3% compared to prior year

    80% confidence
  • Apparel business saw a 7% decline, greater than anticipated, primarily due to changes in retailer ordering behavior amid tariff uncertainty

    80% confidence
  • Intelligent Labels growth rate in 2026 is anticipated to be above what was delivered in 2025, with high-value categories expected to grow at mid-single-digit plus

    80% confidence
  • Continue to drive ongoing productivity all the time in terms of ELS savings, looking at reducing scrap, being more efficient in our operations

    80% confidence
  • Does not anticipate an increase in customer acquisition costs and feels confident in the company's paper supply risk management

    80% confidence
  • We're anticipating Intelligent Labels growth rate in 2026 to be above what we delivered in 2025, and expects high-value categories to grow at mid-single-digit plus

    80% confidence
  • Walmart announcement increased pipeline interest for Intelligent Labels

    80% confidence
  • Restructuring benefits are expected to be somewhat balanced across the year

    80% confidence
  • Ongoing investments in digital capabilities, automation, and AI will enable additional operational productivity and fixed cost innovation, strengthen service and quality, shorten innovation cycles and provide more data-driven solutions

    80% confidence
  • Company feels confident in paper supply risk management

    80% confidence
  • Temporary savings headwind is on an order of magnitude basis probably pretty similar to the size of the restructuring actions, approximately $50 million

    80% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,985
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,985 hechos verificados con la fuente5,351 documentos fuente archivados
Consulta estos datos → isubstrate.com
Avery Dennison outlines 6% Q1 2026 EPS growth target as high-value category mix accelerates — Source | Via News | es.VIA.NEWS